Introduction {#sec1-1}
============

Facial aesthetics are of major importance for individuals seeking cosmetic medical treatment. So much so that several individuals seek professional help to address psychosocial problems caused by an unaesthetic facial appearance.\[[@ref1]\] Of these problems, commonly reported is that of a "gummy smile" (GS).

An excessive display of gingival (gum) tissue while smiling is referred to as "gummy smile". This term is well known to health care givers delivering cosmetic treatment for, e.g., dermatologists. When a more than acceptable (excessive) amount of gum tissue is visible during smiling and/or, even during speech it constitutes an aesthetic problem. Several treatment modalities have been put forth for its management. These include both surgical and nonsurgical interventions such as orthognathic surgery.\[[@ref2][@ref3][@ref4]\] orthodontic treatment using temporary anchorage devices,\[[@ref5]\] crown lengthening procedures,\[[@ref6]\] muscle resection,\[[@ref7]\] and lip re-positioning.\[[@ref8]\]

When caused due to a hyperfunctional upper lip musculature, orthodontic treatment alone is unable to resolve the issue completely as it primarily addresses the hard tissue and not the adjacent soft tissue matrix. Many individuals reject treatment plans involving orthognathic surgery that would help correct lip musculature. Surgical procedures can cause extreme discomfort, edema, swelling; they may lead to relapse and undesirable outcomes such as infection, scar contraction, etc.

Neurotoxins such as botulinum toxin (BTX) have documented use in the dermatologic office for management of keloids, hypertrophic scars, pemphigus like dermatosis, genodermatosis, acne inversa, psoriasis, facial erythema, eccrine nevus, etc. Botulinum toxin type A (BTX-A) has also been used for effective management of hyperfunctional musculature.\[[@ref9][@ref10][@ref11]\] The mechanism of action of BTX is that, it cleaves the synaptosomal-associated protein (SNAP-25) and inhibits the release of acetylcholine, thereby preventing muscle contraction. There are seven serologically distinct types of BTX available, of which type A (BTX-A) seems to be the most potent and is most frequently used in clinical practise. Polo has demonstrated that usage of BTX-A is an effective and minimally invasive technique to achieve a reduction in gingival display for patients with hyperfunctional lip elevator muscles.\[[@ref9]\] These findings are corroborated by similar investigations.\[[@ref12][@ref13][@ref14]\]

The purpose of this study is to evaluate the role of BTX-A as an adjunctive treatment modality to orthodontic treatment wherein gummy smile is due to a hyperfunctional upper lip musculature. The null hypothesis established is that there is no significant difference in gingival display on smiling after administration of BTX-A.

Materials and Methods {#sec1-2}
=====================
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### Subjects {#sec3-1}

A total of 10 patients between the ages of 18--27 years, who presented with a chief complaint of excessive gum display while smiling were recruited. Sample size was measured after conducting a power analysis keeping in mind previous publications on the use of botulinum toxin for management of gummy smile. On pretreatment examination, at a full unopposed smile the gingival display ranged from 6 to 9 mm in the incisor region, and in the buccal region the gum display was observed to be 5--8 mm. During pretreatment examination, standardized frontal photographs at rest and at smiling were obtained (T0) \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]; also measurements of the amount of gingival display while smiling were recorded in mm. Clinical examination pointed to a hyperfunctional upper lip musculature.

![(a) Frontal photograph at rest demonstrating lip incompetency (T0). (b) Frontal photograph while smiling displaying an unaesthetic gummy smile (T0)](IDOJ-10-560-g001){#F1}

After assessing the diagnostic records, patients were informed about the need of orthodontic treatment and the possibility of a surgery to address the hypermobile upper lip. Patients rejected the surgical option. They were later educated about the use of BTX-A neurotoxin to address the upper lip to which they agreed. Complete medical examination was done for all patients and systemic disorders were ruled out. Informed consent was obtained from all patients.

After orthodontic treatment, it was seen that about 6--8 mm of gingival display at smiling still persisted, and even at rest the lips were incompetent. At this stage, it was decided to inject BTX-A neurotoxin. BTX-A (Botox, Allergan, Irvine, CA, USA) was injected at the "Yonsei point" as described by Hwang *et al.*\[[@ref12]\] BTX-A was supplied as a freeze-dried powder of 100 units and was re-constituted with 2 mL normal saline (0.9%) solution to make a 5.0 units/0.1 mL dose according to the manufacturer\'s instructions, and 3.0 units was injected at each "Yonsei point" on both sides. Patients were then recalled at 15 days (T1) to obtain facial photographs and measurements regarding the gingival display.

### Data collection {#sec3-2}

Standardized pre-treatment photographs of patients while smiling were obtained. Measurement of gingival display in the incisor region was recorded. 15 days after BT injection, the patients were recalled and standardized frontal photographs at rest and while smiling where obtained (T1) \[Figure [2a](#F2){ref-type="fig"} and [b](#F2){ref-type="fig"}\].

![(a) Frontal photograph at rest demonstrating an improvement in lip posture (T1). (b) Frontal photograph while smiling presenting a reduction in gum display (T1)](IDOJ-10-560-g002){#F2}

Statistics {#sec1-3}
==========

All statistical analyses were performed using Statistical Package for the Social Sciences for Windows (v. 10.0; SPSS, Chicago, Ill, USA). Descriptive analysis was performed and calculated for gingival display at T0 and T1 as defined earlier \[[Table 1](#T1){ref-type="table"}\]. Comparisons between the two intervals with respect to gingival display were made using paired sample Student\'s *t*-test (two tailed). In this study, the level of significance for Student\'s *t*-test was determined as *P* \< 0.05.

###### 

Descriptive analysis at T0 and T1

  Interval   *n*   Mean     Standard deviation   *t*       df   *P*    Confidence interval, 95%   Significance
  ---------- ----- -------- -------------------- --------- ---- ------ -------------------------- --------------
  T0         10    7.5 mm   ±1.35                16.5168   9    4.87   \[3.7111, 4.8889\]         0.05\*
  T1         10    3.2 mm   ±0.91                                                                 

\*Statistically significant difference at *P*\<0.05

Results {#sec1-4}
=======

At T0, gingival display while smiling was measured to be 7.5 ± 1.35 mm, while at T1 it was reduced to 3.2 ± 0.91 mm. Descriptive statistics are given in [Table 1](#T1){ref-type="table"}. The measured *t* value obtained is *t* 16.5168. The *P* value returned by Student\'s *t* test is 4.87. This is greater than the critical value for the sample (degrees of freedom, df = 9). The null hypothesis established was thus rejected. This shows that there was a statistically significant difference in the amount of gingival display while smiling between T0 and T1 (*P* \< 0.05).

Discussion {#sec1-5}
==========

Smile is a dynamic voluntary activity which occurs between the framework of the circumoral musculature, teeth and bony maxillary morphology. The upper lip elevator muscles namely levator labii superioris, levator labii superiosis alaeque nasi, and zygomaticus minor play a major role while smiling. A hyperfunction of these muscles increases the muscular capacity to raise the upper lip while smiling, thereby giving rise to a gummy smile.\[[@ref15]\] Effective management would need denervation of these three muscles. In order to achieve this, BTX-A was injected at the "Yonsei point" \[[Figure 3](#F3){ref-type="fig"}\]. The "Yonsei point" lies at center of the muscle vectors of levator labii superioris, levator labii superioris alaeque nasi, and zygomaticus minor, and all the three elevator muscles converge at this point lateral to the ala.\[[@ref12]\] It is a safe and reproducible point to inject BTX-A. Although other sites have also been suggested,\[[@ref16]\] it is recommended that the "Yonsei point" is used because it affects the whole of levator labii superioris, levator labii superioris alaeque nasi, and zygomaticus minor, rather than influence individual activation of each muscle. When injected, BTX-A caused a denervation of these muscle by blocking neuromuscular transmission by inhibiting the release of acetylcholine.\[[@ref17]\] This denervation in turn causes a reduction in hyperactive muscle activity.

![Location of "Yonsei Point"](IDOJ-10-560-g003){#F3}

This investigation was carried out on ten female individuals who complained of unaesthetic excessive gingival display while smiling. The gingival display on smiling was measured before BTX-A administration (7.5 ± 1.35 mm) (T0) and 15 days after BTX-A injection (3.2 ± 0.91 mm) (T1). The results of the study showed that there was a statistically significant reduction in the amount of gingival display while smiling (*P* \<.05). This helped in achieving the goal of improving facial aesthetics by eliminating excessive gingival display. These findings were similar to those reported by Polo,\[[@ref9]\] Hwang *et al.*,\[[@ref12]\] Mazucco and Hexsel,\[[@ref10]\] Gracco,\[[@ref13]\] and Suber *et al.*\[[@ref14]\]

The authors caution that diligence must be observed before injecting BTX-A due to it\'s reported potential side effects, such as allergic reactions, trouble breathing and/or swallowing, muscle stiffness, dystonia, etc.,\[[@ref18]\] and, should be administered by qualified dermatologists only. There were no adverse effects observed in any of the patients administered with BTX-A, thereby making it a relatively safer option when compared to other surgical options. In this investigation, only 3.0 units were injected at each "Yonsei point," this is significantly lesser than previous reported studies like Suber *et al.* where an average of 5.0 units were injected bilaterally at three sites,\[[@ref14]\] or other studies\[[@ref9][@ref10]\] wherein 2.5 units were injected at three different sites to denervate the levator labii superioris, levator labii superioris alaeque nasi, and zygomaticus minor muscles individually. Hence, it can be inferred that the technique employed in this study uses a much lesser quantity of neurotoxin at a single site than that utilized in previous studies, and is much safer.

Further, studies are needed to rigorously assess the effectiveness and safety of this method. It would also be useful if further investigations are conducted to assess the long-term stability of treatment effects with a larger sample size.

Gummy smile when caused due to hyperactivity of the lip elevator muscles is not amenable to orthodontic treatment alone, and can be best treated by adjunctive administration of BTX-A.

Conclusion {#sec1-6}
==========

Administration of BTX-A is a reliable and minimally invasive method to reduce excessive gingival display in individuals with hyperfunctional upper lip elevator musculatureIt is a useful adjunctive treatment modality in the management of gummy smile not amenable to orthodontic treatment alone.
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